D. Boral Capital Reiterates "Buy" Rating for Urogen Pharma (NASDAQ:URGN)

Urogen Pharma (NASDAQ:URGN - Get Free Report)'s stock had its "buy" rating reiterated by D. Boral Capital in a note issued to investors on Monday,Benzinga reports. They currently have a $25.00 price target on the stock. D. Boral Capital's target price points to a potential upside of 82.35% from the stock's previous close.

Other research analysts also recently issued reports about the company. HC Wainwright upgraded Urogen Pharma from a "neutral" rating to a "buy" rating and set a $50.00 price objective on the stock in a report on Monday, June 16th. The Goldman Sachs Group set a $16.00 price target on Urogen Pharma and gave the company a "neutral" rating in a report on Friday, June 13th. Scotiabank reiterated an "outperform" rating on shares of Urogen Pharma in a report on Friday, June 13th. Oppenheimer set a $31.00 price target on Urogen Pharma and gave the company a "buy" rating in a report on Friday, June 13th. Finally, Guggenheim reiterated a "buy" rating and issued a $30.00 price target (up from $15.00) on shares of Urogen Pharma in a report on Friday, June 13th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $32.86.

Urogen Pharma Stock Performance

URGN traded up $0.22 during trading on Monday, hitting $13.71. 827,939 shares of the stock were exchanged, compared to its average volume of 1,082,523. The firm has a 50 day simple moving average of $9.72 and a 200 day simple moving average of $10.26. The firm has a market cap of $632.17 million, a price-to-earnings ratio of -4.31 and a beta of 1.02. Urogen Pharma has a 1 year low of $3.42 and a 1 year high of $18.15.

Urogen Pharma (NASDAQ:URGN - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The company reported ($0.92) EPS for the quarter, missing the consensus estimate of ($0.83) by ($0.09). The firm had revenue of $20.25 million for the quarter, compared to analysts' expectations of $22.71 million. Urogen Pharma had a negative return on equity of 97,487.15% and a negative net margin of 150.68%. As a group, equities analysts anticipate that Urogen Pharma will post -3.12 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Urogen Pharma news, insider Mark Schoenberg sold 5,162 shares of Urogen Pharma stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $7.37, for a total transaction of $38,043.94. Following the completion of the sale, the insider owned 153,378 shares of the company's stock, valued at approximately $1,130,395.86. The trade was a 3.26% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 5.10% of the company's stock.

Institutional Trading of Urogen Pharma

A number of institutional investors and hedge funds have recently added to or reduced their stakes in URGN. CWM LLC lifted its position in Urogen Pharma by 6,047.1% during the 1st quarter. CWM LLC now owns 5,225 shares of the company's stock worth $58,000 after acquiring an additional 5,140 shares during the period. KLP Kapitalforvaltning AS acquired a new stake in Urogen Pharma during the 4th quarter worth about $59,000. Lazard Asset Management LLC acquired a new stake in Urogen Pharma during the 4th quarter worth about $67,000. GAMMA Investing LLC raised its stake in shares of Urogen Pharma by 6,908.4% during the 1st quarter. GAMMA Investing LLC now owns 7,499 shares of the company's stock valued at $83,000 after buying an additional 7,392 shares during the last quarter. Finally, Aquatic Capital Management LLC purchased a new position in shares of Urogen Pharma during the 4th quarter valued at about $101,000. Institutional investors and hedge funds own 91.29% of the company's stock.

About Urogen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.